Nida Khan in TCS Nashik case: Designation disputed, pregnancy cited for bail, police deploy four teams in ongoing manhunt
Fresnillo (LSE: FRES): Can the world’s largest silver miner hold its record gains as 2026 output dips?
TCS CEO corrects three major Nashik facts: Nida Khan was not HR head, unit not shut, no POSH complaints on record
Read More Pharma Industry News Can Protagonist’s icotrokinra become the first oral IL-23 therapy to rival biologics in ulcerative colitis? Positive Phase 2b data for Protagonist Therapeutics’ oral IL-23R inhibitor icotrokinra show strong efficacy and safety in ulcerative colitis; learn what’s next for Phase 3. byVenkateshOctober 10, 2025